Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

Non-interventional Study Investigating How Effective Secondary Prevention Patients Are Treated to Their LDL-C Targets

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00536796

Enrollment

1096

Registered

2007-09-28

Start date

2007-09-30

Completion date

2007-12-31

Last updated

2014-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Carotid Stenosis, Coronary Heart Disease, Diabetes Mellitus, Hyperlipidemias, Peripheral Vascular Diseases

Keywords

Hyperlipidemia, Need-to-treat, NIS, Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes

Brief summary

A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy. Lipid profile and rate of patients who are treated to target (which is \<100mg/dl for patients with high risk and \<70mg/dl for patients at very high risk) are screened (hospital-based specialists). The doctors therapy decisions after the screening and possible reasons for these decisions will be documented. Our aim is to evaluate dosing habits, to evaluate how many patients are treated to their LDL-C target and to underline the importance of treating patients to their cholesterol targets.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Secondary prevention patients with hyperlipidemia and atherosclerosis (coronary heart disease, carotid stenosis, PVD, etc.) and/or diabetes who already receive cholesterol-lowering therapy

Exclusion criteria

* Patients who do not receive cholesterol-lowering therapy

Design outcomes

Primary

Measure	Time frame	Description
Cholesterol levels	After 4 weeks	Cholesterol levels from high risk patients after 4 weeks of cholesterol-lowering drug therapy under target values

Countries

Austria

Outcome results